ACET · Adicet Bio, Inc. · Documents

$2.93 -0.06 (-2.01%) At close · Nov 12

Market Cap

$27.43M

9.36M

Volume · Nov 12 371.41K Avg daily vol (3M) 226.86K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $116.8M 10-K filed Mar 12, 2026 Quarterly report FY2026 Q3 Net loss $18.88M 10-Q filed Nov 5, 2026 Latest results Evaluable LN patients achieved 50% complete renal response at 12 months 8-K filed Nov 5, 2026

2026

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Prula-cel advances as funding uncertainty persists

Adicet Bio, Inc. is advancing prula-cel toward pivotal lupus studies, but substantial doubt exists about continuing as a going concern; nine-month losses were $60.5 million and cash totaled $100.9 million.

Net loss $18.88M Diluted EPS -$1.76

Read from the MD&A section

4 source passages

In September 2026, the Company prioritized development of prula-cel toward potential pivotal studies in systemic lupus erythematosus (SLE), including both lupus nephritis and extra-renal SLE. Based on our current operating plan, we believe that substantial doubt exists about our ability to continue as a going concern for at least twelve months following the filing of this Quarterly Report on Form 10-Q, and we will need to obtain additional funding. We have incurred losses of $60.5 million and $86.3 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had cash, cash equivalents, and short-term investments in treasury securities of $100.9 million. Open the document at this passage

Nov 5

Current report 8-K

Evaluable LN patients achieved 50% complete renal response at 12 months

Adicet Bio reported that 50% of evaluable lupus nephritis patients achieved a complete renal response at 12 months. Third-quarter net loss was $18.9 million, while cash, cash equivalents and short-term investments totaled $100.9 million as of September 30, 2026.

Financial results

4 source passages

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today reported financial results and operational highlights for the third quarter ended September 30, 2026. At 12 months, 50% of evaluable LN patients achieved a complete renal response and 54% of evaluable patients achieved Definition of Remission in Systemic lupus (DORIS) remission. Net Loss: Net loss was $18.9 million, or a net loss of $1.76 per basic and diluted share for the three months ended September 30, 2026. Cash Position: Cash, cash equivalents and short-term investments were $100.9 million as of September 30, 2026. Open the document at this passage

Sep 28

Current report 8-K

Regulation FD disclosure, Other events

Adicet Bio reported Phase 1 prula-cel data as of August 28, 2026: 50% of evaluable lupus nephritis patients achieved complete renal response and 54% achieved DORIS remission at 12 months; pivotal start-up is planned for the fourth quarter of 2026.

Sep 8

Current report 8-K

Regulation FD disclosure AI summary on its way

Sep 1

Current report 8-K

Regulation FD disclosure AI summary on its way

Aug 11

Investor event

Canaccord Genuity 46th Annual Growth Conference AI summary on its way

Aug 5

Current report 8-K

Financial results AI summary on its way